Auto-immunity profile evaluation during different clinical manifestations of Behçet disease in Algerian patients: effect of corticosteroid treatment
- 8 Downloads
Background and aims
Behçet disease (BD) is a chronic multisystem disease. It stands at the crossroads between the auto-immunity and auto-inflammatory disorders. Our study aims to evaluate corticosteroids therapy effects on serum immunoglobulin isotypes and anti-phospholipid auto-anti-body production in Algerian BD patients with different clinical manifestations.
We evaluated serum immunoglobulin isotypes and anti-phospholipid (anti-cardiolipin, anti-β2glycoprotein I, anti-prothrombin) auto-anti-body production using Turbidimetric or Luminex platform assays. Our study was conducted in naïve active BD patients and in corticosteroid-treated patients with different clinical manifestations.
Results and discussion
Our results indicate that IgM, IgG, and IgA levels were higher in naïve active patients. The increase in sera isotypes did not differ according to the clinical manifestation, except for IgA production, which was associated with an increased risk of mucocutaneous and ocular involvement. Interestingly, in corticosteroid-treated active patients, no difference was reported between each clinical subgroup. Furthermore,anti-cardiolipin, anti-β2glycoprotein I and anti-prothrombin auto-anti-body levels were elevated in naïve active patients. Contrary to anti-prothrombin, high anti-cardiolipin and anti-β2glycoprotein I, production differed according to the clinical manifestations and was associated with an increased risk of mucocutaneous and ocular involvement. Importantly, corticosteroid therapy significantly reduced these immune markers regardless of the clinical manifestations.
Our results suggest that high IgA production could be a risk marker of uveitis in naïve active patients. Moreover, concomitant high anti-cardiolipin, anti-β2glycoprotein I and anti-prothrombin production is related to an increased risk of mucocutaneous lesions, ocular and vascular involvement. Collectively, our data indicate the importance of evaluating the corticosteroid effect on immune responses associated with BD to ensure an adequate investigation of each related clinical manifestation.
KeywordsBehçet Immunoglobulin isotypes Auto-anti-bodies
The authors thank the patients and the controls. They also express their gratitude to the Department of Immunology of Dr Md SeghirNEKKACHE Hospital in Algiers.
This work was supported by grants from National Agency for Research and Development (ATRSS, ex ANDRS), project code number43-ANDRS-2011 Algeria.
Compliance with ethical standards
Conflict of interest
The author(s) declare that they have no conflicts of interest with regard to the research, authorship, and/or publication of this article.
This manuscript was approved by all co-authors. The local ethics committee “Algerian National Agency for Research in Health Sciences, ATRSS ex-ANDRS” in compliance with Helsinki declaration has approved our study (Code number 43-ANDRS-2011).
- Alekberova ZS, Prokaeva TB, Reshetniak TM et al (2000) Antiphospholipid anti-bodies in Behcet’s disease. Klin Med 78(5):37–38Google Scholar
- Ataollahi MR, Aflaki E, Nazarinia MA et al (2012) anti-cardiolipin and anti-neutrophil cytoplasmic anti-bodies in Iranian patients with Behcet’s disease. Iran J Immunol 9(4):241–247Google Scholar
- Ekşioglu-Demiralp E, Kibaroglu A, Direskeneli H et al (1999) Phenotypic characteristics of B cells in Behçet’s disease: increased activity in B cell subsets. J Rheumatol 26(4):826–832Google Scholar
- Hamzaoui K, Houman H, Ben Dhifallah I et al (2008) Serum BAFF levels and skin MRNA expression in patients with Behçet’s disease. Clin Exp Rheumatol 26(4 Suppl 50):S64–71Google Scholar
- Kang SE, Lee SJ, Lee JY et al (2017) Serum levels of IgG anti-bodies against alpha-enolase are increased in patients with Behçet’s disease and are associated with the severity of oral ulcer, erythrocyte sedimentation rates, and C-reactive protein. Clin Exp Rheumatol 35 Suppl 108(6):67–74Google Scholar
- Park SJ, Oh JY, Shin JI (2014) Could increased IgA induced by BAFF be the cause of IgA nephropathy development in Behcet’s disease? Comment on: Behcet’s disease and IgA nephropathy (Rheumatol Int. 2012 Jul; 32(7):2227–9). Rheumatol Int 34(2):283–284. https://doi.org/10.1007/s00296-013-2667-6 CrossRefGoogle Scholar
- Tursen U (2009) Activation markers in Behcet’s disease. Urkderm Arch Turk Dermatol Venerol 43:74–86Google Scholar